A universal cure for HIV will almost certainly not be available by 2030. While several promising strategies are in early clinical trials, none are close to becoming a widely accessible treatment. The global 2030 goal for HIV is not about finding a cure at all. It’s about reducing new infections and AIDS-related deaths by 90% compared to 2010 levels, primarily through better testing, treatment, and prevention.
That said, real progress is happening in cure research. Understanding where things stand, and what “cure” actually means in the context of HIV, helps make sense of the headlines.
What the 2030 Target Actually Means
When organizations like UNAIDS talk about “ending AIDS by 2030,” they’re not talking about a cure. They define success as a 90% reduction in both new HIV infections and AIDS-related deaths from 2010 levels. The specific benchmarks focus on getting 95% of people living with HIV diagnosed, 95% of those diagnosed on treatment, and 95% of those on treatment with undetectable viral loads. There’s also a target for 90% of people who need prevention tools (like PrEP, condoms, and clean needles) to actually have access to them.
These are treatment and prevention goals, not cure goals. The strategy relies on the fact that antiretroviral therapy already works extremely well at suppressing the virus and preventing transmission. The challenge is getting these tools to everyone who needs them, particularly in sub-Saharan Africa and other regions with the highest HIV burden.
Why HIV Is So Hard to Cure
Antiretroviral therapy can push the virus to undetectable levels in the blood, but it cannot eliminate HIV from the body. The reason is a hidden reservoir of infected cells. When HIV infects certain immune cells, it can insert its genetic code directly into the cell’s DNA and then go silent. These latently infected cells produce no viral proteins, so the immune system doesn’t recognize them as threats and antiretroviral drugs, which target actively replicating virus, can’t touch them either.
The largest known reservoir sits in a type of immune cell called CD4+ T cells. Only about 2% of these cells circulate in the blood. The vast majority live in tissues throughout the body, making the reservoir extremely difficult to access or study. There’s also growing evidence that long-lived immune cells in the brain and other organs can harbor dormant virus. If a person stops taking antiretroviral therapy, even after decades, these silent reservoirs can reactivate and the virus comes roaring back, usually within weeks.
Sterilizing Cure vs. Functional Cure
Researchers pursue two distinct goals. A sterilizing cure means completely eliminating every copy of HIV’s genetic material from the body. A functional cure means the virus remains present at very low levels but the person’s immune system controls it without medication, keeping viral loads undetectable indefinitely. Most scientists consider a functional cure the more realistic near-term goal, since wiping out every last infected cell in the body is an enormous challenge.
People Who Have Been Cured (and Why It Doesn’t Scale)
A handful of people have achieved what appears to be a sterilizing cure. The first, known as the Berlin patient, received a bone marrow stem cell transplant in 2009 for leukemia and remained HIV-free for 12 years. The London patient, treated for Hodgkin lymphoma with a similar transplant, has been in remission for years as well. A third case, the first in a woman, used a different approach: a dual transplant combining umbilical cord blood stem cells with bone marrow from an adult donor.
In each case, the donor cells carried a rare genetic mutation that makes cells resistant to HIV infection. The transplant essentially replaced the patient’s immune system with one the virus couldn’t easily infect. But bone marrow transplants are dangerous, expensive, and require a matched donor with that specific genetic trait, which only about 1% of people of European descent carry. These procedures are only performed when a patient also has a life-threatening cancer that justifies the risk. They offer proof that a cure is biologically possible, but they are not a path to curing the 39 million people currently living with HIV worldwide.
Gene Editing With CRISPR
One of the most watched experimental approaches uses gene-editing technology to cut HIV’s DNA directly out of infected cells. A therapy called EBT-101, developed by researchers at Temple University and Excision BioTherapeutics, entered a Phase 1/2 clinical trial as the first CRISPR-based treatment for HIV. The therapy is delivered as a single intravenous infusion designed to find and remove viral DNA from cells throughout the body. Preclinical work showed it could eliminate HIV DNA from infected cells in laboratory settings.
The trial is evaluating both safety and whether participants can stop antiretroviral therapy without the virus rebounding. Results are still early, and even optimistic timelines suggest years of additional trials before this approach could reach broader use. Manufacturing a personalized gene therapy at scale, particularly for low-income countries where most people with HIV live, presents enormous logistical and cost barriers that haven’t been solved for any gene therapy yet.
Shock and Kill vs. Block and Lock
Two competing strategies aim to deal with the latent reservoir without gene editing. The “shock and kill” approach tries to wake up dormant virus in hiding cells using drugs called latency-reversing agents. Once the virus is active, the immune system or additional therapies could theoretically recognize and destroy those cells. The “block and lock” approach works in the opposite direction: it tries to permanently silence the virus so deeply that it can never reactivate, even without medication.
Neither strategy has achieved durable remission in clinical trials so far. The shock-and-kill method faces a fundamental problem: the most effective way to activate latent virus is broad immune stimulation, which causes serious side effects and can actually increase the number of infected cells. Researchers are searching for more targeted drugs that can flip the switch on dormant virus without activating the entire immune system. Block-and-lock is at an even earlier stage, with scientists still identifying compounds that can reliably silence HIV gene expression long term.
Engineered Antibodies for Remission
Broadly neutralizing antibodies are lab-engineered immune proteins that can recognize and neutralize a wide range of HIV strains. Clinical trials have tested whether infusing combinations of these antibodies can keep the virus suppressed after a person stops antiretroviral therapy. The results have been mixed. Using a single antibody didn’t work. Combinations of two or more antibodies have kept viral loads suppressed for months in some participants, showing the concept has potential.
The problem is that breakthrough rates remain high. Even trials combining three antibodies saw unacceptable levels of viral rebound, largely because many people harbor HIV strains that are already resistant to one or more of the antibodies. Current testing methods can’t reliably predict whose virus will be sensitive to which antibody combination. This approach may eventually become part of a functional cure strategy, but significant hurdles around resistance remain.
HIV Vaccines Are Still in Early Stages
An effective preventive vaccine would transform the epidemic, but HIV has defeated every major vaccine attempt so far. The virus mutates rapidly, attacks the very immune cells meant to fight it, and hides in reservoirs that the immune system can’t survey. New mRNA vaccine platforms, building on the technology used for COVID-19 vaccines, have brought fresh momentum to the field.
Several mRNA HIV vaccines are in Phase 1 trials. One, developed with the International AIDS Vaccine Initiative, uses a “germline-targeting” strategy designed to train rare precursor immune cells to eventually produce broadly neutralizing antibodies. Another trial is testing mRNA vaccines that encode HIV proteins, causing cells to build virus-like particles that trigger an immune response without any risk of infection. In primate studies, this vaccine reduced the risk of infection per exposure by 79%, and two of seven vaccinated animals remained completely uninfected. These are encouraging signals, but Phase 1 trials only test safety and basic immune responses in small groups. An effective vaccine is likely well beyond 2030.
What’s Realistic by 2030
By 2030, the most tangible progress will come from scaling up existing tools: longer-acting injectable antiretrovirals that replace daily pills, expanded access to PrEP, and better diagnostics in underserved regions. These won’t cure anyone, but they could dramatically reduce new infections and deaths if deployment targets are met.
On the cure front, 2030 will likely bring clearer data from early-phase gene editing and antibody trials, possibly identifying which strategies deserve large-scale investment. A functional cure that works for some people under specific conditions is conceivable within the next decade. A scalable, affordable cure available to the millions who need it most is not. The biological complexity of the latent reservoir, the early stage of most experimental therapies, and the massive gap between a clinical trial success and a globally accessible treatment all point to a timeline that extends well past 2030.